High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses

Blood

Volumn 120, Issue 13, 2012, Pages 2700-2703

  Haroche, Julien ^a,b   Charlotte, Frédéric ^a,b   Arnaud, Laurent ^a,b   Von Deimling, Andreas ^c,d   Hélias Rodzewicz, Zofia ^e   Hervier, Baptiste ^a,b   Cohen Aubart, Fleur ^a,b   Launay, David ^f   Lesot, Annette ^a,b   Mokhtari, Karima ^a,b   Canioni, Danielle ^g,h   Galmiche, Louise ^g,h   Rose, Christian ⁱ   Schmalzing, Marc ^j   Croockewit, Sandra ^k   Kambouchner, Marianne ^l   Copin, Marie Christine ^f   Fraitag, Sylvie ^g,h   Sahm, Felix ^c,d   Brousse, Nicole ^g,h   Amoura, Zahir ^a,b   Donadieu, Jean ^m   Emile, Jean Franco̧is ^e,n   more..

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ UNIV LILLE   (France)

^j UNIVERSITY OF TÜBINGEN   (Germany)

^k RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^l UNIVERSITÉ PARIS 13   (France)

^m ARMAND TROUSSEAU HOSPITAL   (France)

ⁿ HÔPITAL AMBROISE PARÉ   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; B RAF KINASE GENE; DNA EXTRACTION; DNA SEQUENCE; ERDHEIM CHESTER DISEASE; FEMALE; GENE; GENE IDENTIFICATION; GENE MUTATION; HISTIOCYTOSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERDIGITATING DENDRITIC CELL SARCOMA; LANGERHANS CELL HISTIOCYTOSIS; MAJOR CLINICAL STUDY; MALE; NECROBIOTIC XANTHOGRANULOMA; PRIORITY JOURNAL; SINUS HISTIOCYTOSIS; XANTHOMA; XANTHOMA DISSEMINATUM;

EID: 84866596727     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-05-430140     Document Type: Article

References (22)

1. Writing Group of the Histiocyte Society. Histiocytosis syndromes in children. Lancet. 1987;329(1):208-209.
2. Nezelof C, Basset F, Rousseau MF. Histiocytosis X histogenetic arguments for a Langerhans cell origin. Biomedicine. 1973;18(5):365-371.
3. Emile JF, Wechsler J, Brousse N, et al. Langerhans' cell histiocytosis: definitive diagnosis with the use of monoclonal antibody O10 on routinely paraffin-embedded samples. Am J Surg Pathol. 1995;19(6):636-641.
4. LeBoit PE, Burg G, Weedon D, Sarasin A. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Skin. Lyon, France: International Agency for Research in Cancer; 2006.
5. Swerdlow SH, Campo E, Lee Harris N, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research in Cancer; 2008.
6. Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol. 2005;23(27):6771-6790. (Pubitemid 46194105)
7. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954. (Pubitemid 34716871)
8. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
9. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919-1923.
10. Satoh T, Smith A, Sarde A, et al. B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease. PLoS One. 2012;7(4):e33891.
11. Guyot-Goubin A, Donadieu J, Barkaoui M, Bellec S, Thomas C, Clavel J. Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000-2004. Pediatr Blood Cancer. 2008;51(1):71-75. (Pubitemid 351717393)
12. Arnaud L, Hervier B, Néel A, et al. CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood. 2011;117(10):2778-2782.
13. Moreau S, Saiag P, Aegerter P, et al. Prognostic value of BRAF (V600) mutations in melanoma patients after resection of metastatic lymph nodes [published online ahead of print July 7, 2012]. Ann Surg Oncol. doi:10.1245/s10434-012-2457-5.
14. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011;122(1):11-19.
15. Willman CL, Busque L, Griffith BB, et al. Langerhans'-cell histiocytosis (histiocytosis X): a clonal proliferative disease. N Engl J Med. 1994;331(3):154-160. (Pubitemid 24209565)
16. Arnaud L, Gorochov G, Charlotte F, et al. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. Blood. 2011;117(10):2783-2790.
17. Chetritt J, Paradis V, Dargere D, et al. Chester-Erdheim disease: a neoplastic disorder. Hum Pathol. 1999;30(9):1093-1096. (Pubitemid 29427167)
18. Vencio EF, Jenkins RB, Schiller JL, et al. Clonal cytogenetic abnormalities in Erdheim-Chester disease. Am J Surg Pathol. 2007;31(2):319-321. (Pubitemid 46175035)
19. Marchal A, Cuny JF, Montagne K, Haroche J, Barbaud A, Schmultz JL. Associated Langerhans cell histiocytosis and Erdheim-Chester disease. Ann Dermatol Venereol. 2011;138(11):743-747.
20. French Langerhans' Cell Histiocytosis Study Group. A multicentre retrospective survey of Langerhans' cell histiocytosis: 348 cases observed between 1983 and 1993. Arch Dis Child. 1996;75(1):17-24.
21. Montella L, Insabato L, Palmieri G. Imatinib mesylate for cerebral Langerhans'-cell histiocytosis. N Engl J Med. 2004;351(10):1034-1035. (Pubitemid 39166273)
22. Haroche J, Amoura Z, Charlotte F, et al. Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis. Blood. 2008;111(11):5413-5415.